This week we have news of the neutralizing response of the Pfizer-BioNTech vaccine to the new COVID-19 variant; A trial investigated ravulizumab in adults with severe COVID is halted; A rapid blood test for concussions gets the all clear; A novel treatment for chronic kidney disease in patients with type 2 diabetes; And the drug manufacturer Fresenius Kabi announces a voluntary recall of one lot of an NSAID treatment.
The FDA has accepted for Priority Review the NDA for finerenone for chronic kidney disease in patients with type 2 diabetes.
The FDA has granted Priority Review to dapagliflozin (Farxiga) for the treatment of new or worsening CKD.
The FDA has approved the first generic equivalent of Glucagon Emergency Kit (Lilly), according to Amphastar Pharmaceuticals.
As both the vaccine and Tepezza are being manufactured at Catalent, the government has prioritized the manufacturing of the vaccine thereby resulting in cancellation of previously contracted Tepezza orders.
Its been a long year, but the monumental efforts to achieve a COVID-19 vaccine are bearing some fruits, we about that, and also a fully at home diagnostic COVID test, as well as new findings related to glucosamine supplements and a novel treatment for eosinophilic esophagitis. And as ever, one final movie trivia ‘guess the quote’ to end the year!
This week we cover new findings for the diabetes drug sitagliptin in pediatrics; An obesity treatment has its approval expanded; The FDA issue a Complete Response Letter for an outpatient alternative treatment; And news of availability for a transdermal contraceptive patch.
In overall sample of men and women, metformin use was not linked to significantly reduced mortality
Tirzepatide is an investigational dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist that integrates the actions of both incretins into a single molecule.
This slideshow shows drug information for Gimoti. Click here for the complete Gimoti monograph.
